Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice

Genetics and Molecular Research

Volumn 14, Issue 4, 2015, Pages 14253-14261

  Yin, S J ^a   Wang, W J ^a   Zhang, J Y ^a  

^a The People s Hospital of Shouguang   (China)

Author keywords

B7 H3; Nude mice; Osteosarcoma; T cell

Indexed keywords

B7 H3 PROTEIN; CD28 ANTIGEN; MESSENGER RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG; B7 ANTIGEN; CD276 PROTEIN, MOUSE; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER MODEL; CANCER SIZE; CANCER TISSUE; CD3+ T LYMPHOCYTE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOSARCOMA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; BONE TUMOR; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; B7 ANTIGENS; BIOMARKERS, TUMOR; BONE NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICE, NUDE; OSTEOSARCOMA; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 84947218955     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.November.13.9     Document Type: Article

References (23)

1. Botter SM, Neri D and Fuchs B (2014). Recent advances in osteosarcoma. Curr. Opin. Pharmacol. 16: 15-23.
2. Chapoval AI, Ni J, Lau JS, Wilcox RA, et al.(2001). B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat. Immunol. 2: 269-274.
3. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, et al. (2008). Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin. Cancer Res. 14: 5150-5157.
4. Fleuren ED, Versleijen-Jonkers YM, Boerman OC and van der Graaf WT (2014). Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. Biochim. Biophys. Acta 1845: 266-276.
5. Li Y, Flores R, Yu A, Okcu MF, et al. (2011). Elevated expression of CXC chemokines in pediatric osteosarcoma patients. Cancer 117: 207-217.
6. Loeb DM (2009). Is there a role for immunotherapy in osteosarcoma? Cancer Treat. Res. 152: 447-457.
7. Loos M, Hedderich DM, Friess H and Kleef J (2010). B7-h3 and its role in antitumor immunity. Clin. Dev. Immunol. 2010: 683875.
8. Luetke A, Meyers PA, Lewis I and Juergens H (2014). Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat. Rev. 40: 523-532.
9. Merchant MS, Melchionda F, Sinha M, Khanna C, et al. (2007). Immune reconstitution prevents metastatic recurrence of murine osteosarcoma. Cancer Immunol. Immunother. 56: 1037-1046.
10. Moore C, Eslin D, Levy A, Roberson J, et al.(2010). Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr. Blood Cancer 55: 1096-1102.
11. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, et al. (2007). B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67: 7893-7900.
12. Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, et al.(2014). Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int. J. Cancer 137: 73-85.
13. Steinberger P, Majdic O, Derdak SV, Pfistershammer K, et al. (2004). Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J. Immunol. 172: 2352-2359.
14. Sun J, Chen LJ, Zhang GB, Jiang JT, et al. (2010). Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol. Immunother. 59: 1163-1171.
15. Sun M, Richards S, Prasad DV, Mai XM, et al. (2002). Characterization of mouse and human B7-H3 genes. J. Immunol. 168: 6294-6297.
16. Sun Y, Wang Y, Zhao J, Gu M, et al. (2006). B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 53: 143-151.
17. Wang L, Kang FB and Shan BE (2014). B7-H3-mediated tumor immunology: Friend or foe? Int. J. Cancer 134: 2764-2771.
18. Yamato I, Sho M, Nomi T, Akahori T, et al. (2009). Clinical importance of B7-H3 expression in human pancreatic cancer. Br. J. Cancer 101: 1709-1716.
19. Yi KH and Chen L (2009). Fine tuning the immune response through B7-H3 and B7-H4. Immunol. Rev. 229: 145-151.
20. Zang X, Thompson RH, Al-Ahmadie HA, Serio AM, et al. (2007). B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. U. S. A. 104: 19458-19463.
21. Zhang G, Hou J, Shi J, Yu G, et al. (2008). Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 123: 538-546.
22. Zhang G, Xu Y, Lu X, Huang H, et al. (2009). Diagnosis value of serum B7-H3 expression in non-small cell lung cancer. Lung Cancer 66: 245-249.
23. Zheng W, Xiao H, Liu H and Zhou Y (2014). Expression of programmed death 1 is correlated with progression of osteosarcoma. APMIS 123: 102-107.